Evaluation of the Effects of Empagliflozin on Serum Levels of Triglycerides and Cholesterol in Patients with Type 2 Diabetes Mellitus and Hypertriglyceridemia: A Prospective Study

Choobkar, Saeid; Alilou, Mohsen; Mahmoudvand, Golnaz; Karimi Rouzbahani, Arian

doi:10.18502/ijdo.v16i4.17287

Volume 16, Issue 4 (12-2024) IJDO 2024, 16(4): 213-220 | Back to browse issues page

‎ 10.18502/ijdo.v16i4.17287

Mendeley

Zotero

RefWorks

Choobkar S, Alilou M, Mahmoudvand G, Karimi Rouzbahani A. Evaluation of the Effects of Empagliflozin on Serum Levels of Triglycerides and Cholesterol in Patients with Type 2 Diabetes Mellitus and Hypertriglyceridemia: A Prospective Study. IJDO 2024; 16 (4) :213-220
URL: http://ijdo.ssu.ac.ir/article-1-907-en.html

Evaluation of the Effects of Empagliflozin on Serum Levels of Triglycerides and Cholesterol in Patients with Type 2 Diabetes Mellitus and Hypertriglyceridemia: A Prospective Study

Saeid Choobkar

, Mohsen Alilou

, Golnaz Mahmoudvand

, Arian Karimi Rouzbahani ^*

Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. Surgery Education and Researching Network (SERGN), Universal Scientific and Research Network (USERN), Khorramabad, Iran.

Abstract: (126 Views)

Objective: Sodium-glucose cotransporter -2 (SGLT2) inhibitors may improve lipid panels in addition to lowering blood sugar. This research examined how empagliflozin, an SGLT2 inhibitor, affected triglycerides in type 2 diabetes mellitus (T2DM) patients with hypertriglyceridemia.
Materials and Methods: This prospective study was conducted at the Endocrinology Clinic of Shahid Rahimi Hospital in Khorramabad, Iran, in 2020. Thirty-eight patients were included using convenient sampling. The patients’ information including age, gender, body mass index (BMI), Fasting Blood Sugar (FBS), Hemoglobin A1c (HbA1c), 2-hour postprandial blood sugar, serum triglyceride, total cholesterol, High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), serum insulin level, serum creatinine Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Blood pressure, and urine albumin before and three months after receiving empagliflozin 10mg tablets were collected from the clinic medical archives and compared using paired t-test in SPSS software version 22.
Results: BMI, microalbuminuria, BUN, FBS, 2-hour postprandial blood sugar, and HbA1c were improved significantly (P< 0.05) after treatment with empagliflozin. In terms of lipid panels, triglyceride, cholesterol, and LDL levels were improved significantly after treatment with empagliflozin (P< 0.05). HDL levels increased following the treatment but the difference was not statistically significant. There was no linear correlation between HbA1c and HDL (P= 0.183) or triglyceride (P= 0.947) levels.
Conclusion: Empagliflozin improves triglycerides and cholesterol levels in patients with T2DM in addition to its antihyperglycemic effects. It also reduces BMI, blood pressure, BUN, and microalbuminuria.

Keywords: Type 2 Diabetes mellitus, Dyslipidemia, Sodium-glucose co-transporter 2 inhibitor, empagliflozin

Full-Text [PDF 600 kb] (35 Downloads)

Type of Study: Research | Subject: Special
Received: 2023/05/5 | Accepted: 2024/10/20 | Published: 2024/12/16

References

1. Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020 Apr 23;25(8):1987. [DOI:10.3390/molecules25081987]

2. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice. 2018;138:271-81. [DOI:10.1016/j.diabres.2018.02.023]

3. Wu H, Yang S, Huang Z, He J, Wang X. Type 2 diabetes mellitus prediction model based on data mining. Informatics in Medicine Unlocked. 2018;10:100-7. [DOI:10.1016/j.imu.2017.12.006]

4. Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future cardiology. 2018;14(6):491-509. [DOI:10.2217/fca-2018-0045]

5. Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular complications of type 2 diabetes mellitus. Current vascular pharmacology. 2020;18(2):117-24. [DOI:10.2174/1570161117666190502103733]

6. Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. Current vascular pharmacology. 2020;18(2):110-6. [DOI:10.2174/1570161117666190405165151]

7. Vieira R, Souto SB, Sánchez-López E, López Machado A, Severino P, Jose S, et al. Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome-Review of classical and new compounds: Part-I. Pharmaceuticals. 2019;12(4):152. [DOI:10.3390/ph12040152]

8. Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61:2098-107. [DOI:10.1007/s00125-018-4669-0]

9. Chawla G, Chaudhary KK. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(3):2001-8. [DOI:10.1016/j.dsx.2019.04.035]

10. Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CS, et al. Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis. Journal of the American Heart Association. 2020;9(3):e014908. [DOI:10.1161/JAHA.119.014908]

11. Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opinion on Drug Metabolism & Toxicology. 2018;14(11):1113-21. [DOI:10.1080/17425255.2018.1541348]

12. Association AD. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S111-S34. https://pubmed.ncbi.nlm.nih.gov/318 62753/ [DOI:10.2337/dc20-S010]

13. Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes care. 2018;41(8):1801-8. [DOI:10.2337/dc18-0165]

14. Fala L. Jardiance (empagliflozin), an SGLT2 inhibitor, receives FDA approval for the treatment of patients with type 2 diabetes. American health & drug benefits. 2015 Mar;8(Spec Feature):92.

15. Kahl S, Gancheva S, Straßburger K, Herder C, Machann J, Katsuyama H, et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes care. 2020;43(2):298-305. [DOI:10.2337/dc19-0641]

16. Sawada T, Uzu K, Hashimoto N, Onishi T, Takaya T, Shimane A, et al. Empagliflozin's ameliorating effect on plasma triglycerides: association with endothelial function recovery in diabetic patients with coronary artery disease. Journal of Atherosclerosis and Thrombosis. 2020;27(7):644-56. [DOI:10.5551/jat.50807]

17. Ozcelik S, Celik M, Vural A, Aydin B. The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. Northern clinics of Istanbul. 2020 Apr 1;7(2):167-73. [DOI:10.14744/nci.2019.22697]

18. Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research. 2016;13(2):119-26. [DOI:10.1177/1479164115616901]

19. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, et al. Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial. Diabetes, Obesity and Metabolism. 2014;16(2):147-58. [DOI:10.1111/dom.12188]

20. Inzucchi SE, Davies MJ, Khunti K, Trivedi P, George JT, Zwiener I, et al. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2021;23(2):425-33. [DOI:10.1111/dom.14234]

21. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism. 2015;17(10):936-48. [DOI:10.1111/dom.12503]

22. Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137-49. [DOI:10.1016/j.ebiom.2017.05.028]

23. Hierro-Bujalance C, Infante-Garcia C, Del Marco A, Herrera M, Carranza-Naval MJ, Suarez J, et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes. Alzheimer's research & therapy. 2020;12:1-3. [DOI:10.1186/s13195-020-00607-4]

24. Lee MH, Neeland IJ, de Albuquerque Rocha N, Hughes C, Malloy CR, Jin ES. A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: role of visceral fat. Metabolism open. 2022;13:100161. [DOI:10.1016/j.metop.2021.100161]

25. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine. 2016;375(4):323-34. [DOI:10.1056/NEJMoa1515920]

26. Hu X, Yang Y, Hu X, Jia X, Liu H, Wei M, et al. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. Diabetes Obes Metab. 2022 Feb;24(2):228-38. PubMed PMID: 34617381. Epub 20211102. eng. [DOI:10.1111/dom.14570]

27. Ferreira JP, Inzucchi SE, Mattheus M, Meinicke T, Steubl D, Wanner C, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA‐REG OUTCOME trial. Diabetes, Obesity and Metabolism. 2022;24(1):135-41. [DOI:10.1111/dom.14559]

28. Lund SS, Sattar N, Salsali A, Neubacher D, Ginsberg HN. Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials. Diabetes, Obesity and Metabolism. 2021;23(12):2763-74. [DOI:10.1111/dom.14534]

29. Briand F, Mayoux E, Brousseau E, Burr N, Urbain I, Costard C, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65(7):2032-8. [DOI:10.2337/db16-0049]

30. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes care. 2015;38(3):420-8. [DOI:10.2337/dc14-1096]

31. Cherney DZ, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney international. 2018 ;93(1):231-44. [DOI:10.1016/j.kint.2017.06.017]

32. Brands MW, Manhiani MM. Sodium-retaining effect of insulin in diabetes. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2012;303(11):R1101-9. [DOI:10.1152/ajpregu.00390.2012]